The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
Clinical trial NCT07002112 · RECRUITING
Trial details
- NCT number
- NCT07002112
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-23
- Primary completion
- 2027-06-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.